$1,320,000 of CARDINAL HEALTH INC lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to drug pricing, bona fide service fees, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine; Issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages; Issues related to Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS), competitive bidding, reimbursement to home health agencies, and acute hospital care at home services; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5031/S. 3159, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Ensuring Community Access to Pharmacist Services Act; Education around issues facing independent physicians, including S.3822, the Break Up Big Medicine Act. Education on supply chain issues, drug shortages, domestic manufacturing, medical device environmental issues; Issues related to the medical supply chain and transportation. Issues related to tariffs, trade, and U.S. trade policy. Issues related to tariffs, trade, and U.S. trade policy."
You can find more data on corporate lobbying on Quiver Quantitative.
CAH Congressional Stock Trading
Members of Congress have traded $CAH stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CAH stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 10/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
CAH Insider Trading Activity
CAH insiders have traded $CAH stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CAH stock by insiders over the last 6 months:
- AARON E ALT (Chief Financial Officer) sold 2,328 shares for an estimated $524,964
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CAH Hedge Fund Activity
We have seen 668 institutional investors add shares of CAH stock to their portfolio, and 558 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 7,746,239 shares (-77.0%) from their portfolio in Q4 2025, for an estimated $1,591,852,114
- WCM INVESTMENT MANAGEMENT, LLC added 4,032,682 shares (+inf%) to their portfolio in Q4 2025, for an estimated $828,716,151
- BLACKROCK, INC. removed 2,823,035 shares (-9.0%) from their portfolio in Q4 2025, for an estimated $580,133,692
- MILLENNIUM MANAGEMENT LLC removed 1,580,019 shares (-79.6%) from their portfolio in Q4 2025, for an estimated $324,693,904
- HOLOCENE ADVISORS, LP removed 936,677 shares (-48.6%) from their portfolio in Q4 2025, for an estimated $192,487,123
- CITADEL ADVISORS LLC added 934,750 shares (+99.2%) to their portfolio in Q4 2025, for an estimated $192,091,125
- INVESCO LTD. removed 898,506 shares (-25.8%) from their portfolio in Q4 2025, for an estimated $184,642,983
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CAH Analyst Ratings
Wall Street analysts have issued reports on $CAH in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/29/2026
- Mizuho issued a "Outperform" rating on 11/04/2025
- TD Cowen issued a "Buy" rating on 11/03/2025
- UBS issued a "Buy" rating on 10/31/2025
To track analyst ratings and price targets for CAH, check out Quiver Quantitative's $CAH forecast page.
CAH Price Targets
Multiple analysts have issued price targets for $CAH recently. We have seen 9 analysts offer price targets for $CAH in the last 6 months, with a median target of $243.0.
Here are some recent targets:
- Elizabeth Anderson from Evercore ISI Group set a target price of $240.0 on 04/08/2026
- Glen Santangelo from Barclays set a target price of $258.0 on 02/24/2026
- Stephen Baxter from Wells Fargo set a target price of $256.0 on 02/10/2026
- Lisa Gill from JP Morgan set a target price of $243.0 on 02/10/2026
- Steven Valiquette from Mizuho set a target price of $235.0 on 02/06/2026
- Erin Wright from Morgan Stanley set a target price of $245.0 on 01/29/2026
- Daniel Grosslight from Citigroup set a target price of $244.0 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
